

Trans-Allelic Model for Prediction of Peptide:MHC-II Interactions

A. M. Degoot^{1,2,3}, Faraimunashe Chirove², and Wilfred Ndifon¹

¹ African Institute of Mathematical Sciences-(AIMS), 6 Melrose, Muizenberg, Cape Town, South Africa.

² School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Scottsville ave, Pietermaritzburg, South Africa

³ DST-NRF Centre of Excellence in Mathematical and Statistical Sciences (CoE-MaSS), Wits 2050, Gauteng, South Africa

June 12, 2018

Abstract

Major histocompatibility complex class two (MHC-II) molecules are trans-membrane proteins and key components of the cellular immune system. Upon recognition of foreign peptides expressed on the MHC-II binding groove, helper T cells mount an immune response against invading pathogens. Therefore, mechanistic identification and knowledge of physico-chemical features that govern interactions between peptides and MHC-II molecules is useful for the design of effective epitope-based vaccines, as well as for understanding of immune responses. In this paper, we present a comprehensive trans-allelic prediction model, a generalized version of our previous biophysical model, that can predict peptide interactions for all three human MHC-II loci (HLA-DR, HLA-DP and HLA-DQ), using both peptide sequence data and structural information of MHC-II molecules. The advantage of this approach over other machine learning models is that it offers a simple and plausible physical explanation for peptide-MHC-II interactions. We train the model using a benchmark experimental dataset, and measure its predictive performance using novel data. Despite its relative simplicity, we find that the model has comparable performance to the state-of-the-art method. Focusing on the physical bases of peptide-MHC binding, we find support for previous theoretical predictions about the contributions of certain binding pockets to the binding energy. Additionally, we find that binding pockets *P4* and *P5* of HLA-DP, which were not previously considered as primary anchors, do make strong contributions to the binding energy. Together, the results indicate that our model can serve as a useful complement to alternative approaches to predicting peptide-MHC interactions.

1 Introduction

Major histocompatibility complex class two (MHC-II) molecules are surface proteins that exist on the membrane of antigen presenting cells-(APCs) such as macrophages, dendritic cells and B cells. They bind short peptide fragments derived from exogenous proteins and present them to $CD4^+$ helper T cells. Upon the recognition of foreign peptides among those presented by MHC-II molecules, the helper-T cells will initiate proper adaptive immune responses, including enabling sufficient maturation of B cells and cytotoxic $CD8^+$ T cells [1]. Therefore, the binding of peptide to MHC-II molecules is considered to be a fundamental and pre-requisite step in the initiation of adaptive immunity [2, 3]. As such, mechanistic identification of the basic determinants of peptide-MHC-II interactions presents potential for understanding the immune system's mechanisms and improving the process of designing peptide- and proteins-based vaccines.

MHC genes for humans, referred to as Human Leukocyte Antigen-(HLA), are among the most polymorphic genetic elements found within a long continuous stretch of DNA on chromosome 6 [4]. Such high polymorphism reflects the immense contribution of MHC molecules to the adaptive immune system and underpins their capacity to recognize a wide range of pathogens. Nonetheless, some viruses, such as hepatitis C, avian/swine influenza and human immunodeficiency virus (HIV), undergo extensive mutations that allow them to escape recognition by the MHC molecules [5]. MHC genes can be divided into HLA class I, II and III. Molecules corresponding to HLA class I are A, B and C; HLA class II molecules are DP, DQ and DR; HLA class III genes encode for several other immune related proteins and provide support for the former two classes [1, 4].

MHC-II molecules account for the likelihood of organ transplantation and there are well-established associations between many disorders and particular classes of MHC-II molecules. These include the contribution of HLA-DQ genes to insulin-dependent diabetes [6]; HLA-DR genes to multiple-sclerosis; and narcolepsy [7] along with other autoimmune diseases resulting from degeneracy and misregulation in the

process of peptide presentation [8]. Moreover, genetic and epidemiological data have implicated MHC-II molecules in susceptibility to many infectious diseases such as HIV/AIDS, malaria [9] and cancer [10].

Experimental assays for prediction of peptide-MHC-II interactions are often faced with important obstacles, including substantial resources needed for laboratory work, high time and labour demands. This is the case in particular, for experimental work aimed at finding out which promiscuous epitopes bind to specific MHC molecules, a necessary step in the design of peptide-based vaccines which protect against a broad range of pathogen variants. Computational methods, which are more efficient and less costly than biological assays, have been employed to complement these assays. Due to advances in sequencing technologies, immunological data has grown at an unprecedented pace and continues to accrue. This has been exploited in systematic computational analyses of genomes of multiple pathogens to determine the immunoprotective parts that can induce a potent immune response. The results have been the design and development of new vaccine candidates against HIV, influenza and other hyper-variable viruses [11]. Use of computational methods has significantly reduced experimental effort and costs by up to 85% [12].

Many immunoinformatics methods for prediction of peptide-MHC interactions, for both class I and II, have been developed based on machine learning approaches such as simple pattern motif [13], support vector machine (SVM) [14], hidden Markov model (HMM) [15], neural network (NN) models [16, 17], quantitative structure-activity relationship (QSAR) analysis [18], structure-based methods, and biophysical methods [2, 19, 20, 21]. These methods can be divided into two categories, namely, intra-allele (allele-specific) and trans-allele (pan-specific) methods. Intra-allelic methods are trained for a specific MHC allele variant on a limited set of experimental peptide binding data and applied for prediction of peptides binding to that allele. Because of the extreme polymorphism of MHC molecules, the existence of thousands of allele variants, especially for HLA-II genes, combined with the lack of sufficient experimental binding data, it is impossible to build a prediction model for each allele. Thus, trans-allele and general purpose [22] methods like *MULTIRTA* [2], *NetMHCIIpan* [17] and *TEPITOPEpan* [23] have been developed using richer peptide binding data expanding over many alleles or even across species [17]. The trans-allelic models are often designed to extrapolate either structural similarities or shared physico-chemical binding determinants among HLA genes, in order to predict affinities for alleles that are not even part of the training dataset. These models generally have better predictive performances and a wide range of potential applications compared to the intra-allelic models.

Most of the existing trans-allelic models for MHC-II are extended versions of their earlier intra-allelic counterparts: *TEPITOPEpan* [23] was extended from *TEPITOPE* [24]; *MULTIRTA* [2] evolved from *RTA* [19]; and the series of *NetMHCIIpans* (1.0, 2.0, 3.0, and 3.1) [16, 25, 17, 26] were generalized from the NN-align [27] method. In the same vein, in this paper we present a trans-allele method, an extension of our previous method [20], for prediction of peptide-HLA class II interactions based on biophysical ideas.

The remarkable strength of the method presented here over other existing advanced data driven approaches is its physical basis. We formulate the process of binding affinity between peptide and MHC-II molecule as an inverse problem of statistical physics. From the observable macroscopic (bound and unbound) states of experimental data we compute the microscopic parameters (Hamiltonians for amino acid residues involved in the interaction) that govern the system. In fact, many problems in computational biology can be solved in a such way [28, 29], taking advantage of the availability of vast amount of genomic data and high resolution structural information. Solutions obtained using this approach are more plausible and physically interpretable than those obtained using mere sequence-based methods [2, 20]. Additionally, because sparsity is a hallmark feature of biological processes, we adjust the model's parameters via incorporating an L_1 regularization term into the model. The L_1 constraint, commonly named *Lasso*, promotes sparsity and improves the predictive performance of the model on novel data.

The rest of this paper is organized as follows: In Section 2, we describe the idea of MHC-II polymorphic residue groups, which is employed to capture structure similarity among MHC-II alleles. In Section 3, we define our methodology and formulate the learning function. After that we briefly describe the benchmark dataset used to test the predictive performance of the model in Section 4 and present the results in Section 5. Finally, in Section 5.3 we summarize and discuss our results and compare our method with the state-of-the-art method.

2 MHC-II Polymorphic Residue Groups

Crystal structures revealed that an MHC molecule is a combination of two domains, an α helix and a β sheet, linked together to form a Y-shaped groove which is used to locate peptides, and both domains equally contribute to the binding affinity. For HLA-I molecules, the β domain is largely conserved and variation occurs mostly in the α domain. On the other hand, polymorphism occurs in both domains of HLA-II molecules; except for HLA-DR alleles, where the variation takes place in the β domain. Additionally, the peptide binding groove of the HLA-II is open at both ends, which allows binding peptides of variable lengths, ranging from 9 to 30 amino acid residues, or even an entire protein [26, 30]. This is in contrast to the peptide binding groove of the HLA-I alleles, which accommodate only short peptides of lengths ranging from 8 to 11 amino acids. This flexible constraint on peptide lengths together with its immense polymorphism, contribute to a lower predictive performance of computational methods for peptide-MHC-II interactions compared to MHC-I methods [2, 22].

The notion of MHC polymorphic residue groups, introduced by Bordner et. al [2], is based on a simple observation of an intrinsic (independent of peptide) feature of the MHC-II binding groove. Although a peptide could bind to an MHC-II molecule in various registers, due to the open-ended nature of the MHC-II binding groove, the strength of the binding affinity is primarily determined by 9 residues occupying the binding groove pockets. Interestingly, most of polymorphism in MHC-II genes occurs at these binding pockets (see the discussion in Section 5.3).

From the limited available crystallographic structural data of peptide-MHC-II complexes for a few MHC-II molecules from the Protein Data Bank-(PDB) [31] (summarized in **Table ??** in the supplementary material), sets of important positions for the polymorphic residues in the binding groove that contact one or more peptide binding cores and are within a distance of not more than 4Å [2, 17, 32] in one or more of the MHC-II complex structures can be extracted. Then, by extrapolating the similarities among MHC molecules, their corresponding residues in different genes are determined using multiple sequence analysis, (MSA) [33]. Exploiting the fact that HLA-DR alleles are polymorphic only in the β domain and have the same α domain, the polymorphic residue groups for HLA-DR are extracted from its β domain sequences. Similarly, relying on the assumption of symmetric contribution between α and β domains to the binding affinity [2], residue groups for HLA-DP and HLA-DQ were also extracted from the β domain.

Next, the set of polymorphic residues that always co-occur at the specified positions are clustered into the same group. The rationale of clustering polymorphic residue groups, rather than individual residues, is to avoid over-parametrization of the model. **Table ??** in the supplementary material shows such polymorphic residue groups for HLA-DRB, HLA-DP and HLA-DQ alleles, assembled by the procedures described above.

3 Trans-Allele Model

In our previous intra-allele model [20] the probability of peptide $P^{(k)}$ to bind an MHC molecule $M^{(T^{(k)})}$ was computed as follows:

$$\pi(P^{(k)}, M^{(T^{(k)})}) = \frac{1}{1 + e^{\delta E^{(k)}}}, \quad (1)$$

where $\delta E^{(k)}$ is the change in binding energy in terms of the sum of the differences of first- and second-order Hamiltonians between the bound and unbound states. Specifically, $\delta E^{(k)}$ is given by

$$\delta E^{(k)} = \underbrace{\sum_{i=1}^{|P^{(k)}|} \delta H^{(1)}(a_i) + \sum_{i=1}^9 \delta H^{(1)}(b_i)}_{\text{first-order Hamiltonians}} + \underbrace{\delta S + \sum_{i=1}^{|P^{(k)}|} \sum_{j=1}^9 \sum_{r=1}^R \delta H^{(2)}(a_{ir}^{(k)}, b_j)}_{\substack{\text{per residue-residue interactions} \\ \text{second-order Hamiltonians}}}, \quad (2)$$

in which $|P^{(k)}|$ is the length of peptide k , R is the number of all possible configurations (registers) in which the peptide binds to the particular MHC molecule, and δS is the difference in entropy between the bound and unbound states.

For the trans-allele model, two changes were introduced into the second term of **Eq(2)**. First, instead of residue-residue interaction, $\delta H^{(2)}(a_{ir}^{(k)}, b_j)$, with $a_{ir}^{(k)}$ on the peptide sequence and b_j on the MHC binding pocket, we rather focus on residue-polymorphic group interaction, $\delta H^{(2)}(a_{ir}^{(k)}, g_{jn})$, where g_{jn} is residue group number n of position j as defined in Section 2. Next, we introduce a binary operator $T(k, j, n)$ that equals 1 if the MHC molecule type, $M^{(T(k))}$, corresponding to peptide $P^{(k)}$ contains polymorphic residue group n at the set of pre-determined positions of pocket j , and equals 0 otherwise. Hence, $\delta E^{(k)}$ is given by

$$\delta E^{(k)} = \underbrace{\sum_{i=1}^{|P^{(k)}|} \delta H^{(1)}(a_i) + \sum_{i=1}^9 \delta H^{(1)}(b_i) + \delta s}_{\text{first-order Hamiltonians}} + \overbrace{\sum_{i=1}^{|P^{(k)}|} \sum_{j=1}^9 \sum_{r=1}^R \sum_{n=1}^{G(j)} \delta H^{(2)}(a_{ir}^{(k)}, g_{jn}) T(k, j, n)}^{\text{per residue-group interactions}} \underbrace{\hspace{10em}}_{\text{second-order Hamiltonians}}, \quad (3)$$

where $G(j)$ is the number of polymorphic residue groups for binding pocket j . Column two of **Table ??** in the supplementary material shows $G(j)$, $j = 1, 2, \dots, 9$, for HLA-DR, HLA-DP, and HLA-DQ alleles.

Let Δ denote the model's parameters. Using Equations (1) and (3) we formulate, through the maximum likelihood approach, the following cost function:

$$\mathcal{L}(P, M|\Delta) = \underset{\{\Delta\}}{\operatorname{argmin}} \left(\sum_{k=1}^K G^k(\Delta^k) + \lambda \mathcal{P}(\Delta) \right), \quad (4)$$

where $G^k(\Delta)$ is the empirical loss function given by

$$G^k(\Delta) = y^k \log(\pi^k(\Delta)) + (1 - y^k) \log(1 - \pi^k(\Delta)), \quad (5)$$

and $y^k \in \{0, 1\}$ is the experimental value; $y = 1$ for binding peptides and $y = 0$ for non-binding ones. $\lambda \mathcal{P}(\Delta)$ is a regularization term with the form

$$\lambda \mathcal{P}(\Delta) = \lambda \|\Delta\|_1 = \lambda \sum_{i=1}^d |\Delta_i|, \quad (6)$$

where $\lambda > 0$ is a hyper-parameter and d is the dimension of parameter vector Δ , which varies depending on the type of MHC-II molecule. The L_1 constraint penalty term $\mathcal{P}(\Delta)$, also known as Lasso [34], has an important role in the model. As the model is defined on a large number of parameters ($d = 2321, 561$ and 401 for HLA-DR, HLA-DP and DQ molecules, respectively) a few parameters are expected to contribute to the binding affinity while the rest are expected to be noisy. Lasso has the capability to filter out the noisy parameters by inducing sparsity in the model, as it shrinks most of the parameter values to zero, and avoids data over-fitting. The hyper-parameter λ controls the degree of sparsity of the model; the larger the value of λ the more sparse the model. **Eq(4)** is a non-linear and non-smooth function; due to the L_1 constraint. But it is a convex function and we solved it, after quadratic approximation, by means of an iterative, cyclic coordinate descent approach using a soft-thresholding operator. This learning function takes the form of a generalized linear model and the algorithm we used to solve it is both fast and efficient. Details of this optimization method are found in Friedman et. al [35] and are summarized in the supplementary material.

4 Binding Affinity Dataset

The model has been developed by using both quantitative peptide binding data and MHC-II molecule sequences. We obtained a total of 51023 peptide-binding data for 24 HLA-DR, 5 HLA-DP and 6 HLA-DQ from the IEDB database [36], which is, to the best of our knowledge, the largest benchmark dataset publicly available in this field. This dataset was used to develop NetMHCIIpan [17], the state-of-the-art method. The binding affinities data were given in the form of log-transformed measurements of the IC_{50} (half maximum inhibition concentration) according to the formula $1 - \log(IC_{50})/\log(50,000)$ [37]. We dichotomized these

data using a moderate threshold of IC_{50} 500 nM ($\equiv 0.426$ of log-transformed data). Peptides with IC_{50} less than or equal 500 nM (≥ 0.426 of log-transformed value) were considered as binders, and non-binders otherwise.

Amino acid sequences for the MHC-II alleles used in this study were obtained from the **EMBL-EBI** online-database [38], (<ftp://ftp.ebi.ac.uk/pub/databases/ipd/imgt/hla/fasta>). **Table 1** gives a summary of the peptide binding dataset used to develop the method.

Table 1: Overview of the MHC-II peptide binding data utilized in this study.

Allele Name	HLA-Index	#of peptides	#of binders	% of binders
HLA-DR Molecules				
<i>DRB1*01:01</i>	HLA00664	7685	4382	57.02
<i>DRB1*03:01</i>	HLA00671	2505	649	25.91
<i>DRB1*03:02</i>	HLA00673	148	44	29.73
<i>DRB1*04:01</i>	HLA00685	3116	1039	33.31
<i>DRB1*04:04</i>	HLA00689	577	336	58.23
<i>DRB1*04:05</i>	HLA00690	1582	627	39.63
<i>DRB1*07:01</i>	HLA00719	1745	849	48.65
<i>DRB1*08:02</i>	HLA00724	1520	431	28.36
<i>DRB1*08:06</i>	HLA00732	118	91	77.12
<i>DRB1*08:13</i>	HLA00739	1370	455	33.21
<i>DRB1*08:19</i>	HLA00745	116	54	46.55
<i>DRB1*09:01</i>	HLA00749	1520	621	40.86
<i>DRB1*11:01</i>	HLA00751	1794	778	43.37
<i>DRB1*12:01</i>	HLA00789	117	81	69.23
<i>DRB1*12:02</i>	HLA00790	117	79	67.52
<i>DRB1*13:02</i>	HLA00798	1580	493	31.20
<i>DRB1*14:02</i>	HLA00834	118	78	66.20
<i>DRB1*14:04</i>	HLA00836	30	16	53.33
<i>DRB1*14:12</i>	HLA00844	116	63	54.31
<i>DRB1*15:01</i>	HLA00865	1769	709	40.08
<i>DRB3*01:01</i>	HLA00887	1501	281	18.72
<i>DRB3*03:01</i>	HLA00902	160	70	43.75
<i>DRB4*01:01</i>	HLA00905	1521	485	31.89
<i>DRB5*01:01</i>	HLA00915	3106	1280	41.21
HLA-DP Molecules				
<i>DPA1*01:03 – DPB1*02:01</i>	HLA00517	1404	538	38.32
<i>DPA1*01:03 – DPB1*04:01</i>	HLA00521	1337	471	35.23
<i>DPA1*02:01 – DPB1*01:01</i>	HLA00514	1399	597	42.67

Continued on next page

Table 1 – continued from previous page

<i>DPA1*02:01 – DPB1*05:01</i>	HLA00523	1410	443	31.42
<i>DPA1*03:01 – DPB1*04:02</i>	HLA00522	1407	523	37.17
HLA-DQ Molecules				
<i>DQA1*01:01 – DQB1*05:01</i>	HLA00638	1739	522	30.02
<i>DQA1*01:02 – DQB1*06:02</i>	HLA00646	1629	813	49.91
<i>DQA1*03:01 – DQB1*03:02</i>	HLA00627	1719	386	22.46
<i>DQA1*04:01 – DQB1*04:02</i>	HLA00637	1701	559	32.86
<i>DQA1*05:01 – DQB1*02:01</i>	HLA00622	1658	549	33.11
<i>DQA1*05:01 – DQB1*03:01</i>	HLA00625	1689	863	51.10
Total		51023	20255	39.70

Table 1: The first column gives the names of the 34 genes used to develop the method, distributed as 24, 5, 6 for HLA-DR, HLA-DP and HLA-DQ genes respectively. The second column represents the index for each allele in the **EMBL-EBI** database [38]. The third and fourth columns give the total number of peptide and the number of binder peptides, respectively, per allele. The last column shows the percentage of binder peptides. Binder peptides were identified using an IC_{50} binding cut-off of 500 nM, as in previous studies [2, 16, 17, 27]. The last row presents the overall statistics for the last three columns.

5 Results

This section presents prediction results of the model obtained from the dataset of three MHC-II allotypes as described in Section 4. We applied a five-fold cross validation analysis to the model and compared it against its intra-allelic version (**Table ??** in the supplementary material). We also examine its predictive performance on data which were previously unseen by the model.

5.1 Performance of the trans-allele model

We tested the predictive performance of the model by using five fold cross validation. Figure 1 shows results of the test done using alleles belonging to the three MHC-II loci considered in this study. The performance was measured in terms of area under the curve (AUC) [39] values, which range between 0 and 1. The higher the AUC value the better the predictive performance of model. Values below 0.5 reflect a worse performance than a random test. The model has an excellent performance for HLA-DP alleles (average AUC value = 0.930), and a good predictive power for both HLA-DQ and HLA-DR alleles (average AUC values = 0.830 and 0.802, respectively).

5.2 Comparing the intra-allele vs trans-allele methods

Table ?? in the supplementary material shows AUC values obtained with the intra-allele and trans-allele versions of the model. For the intra-alleles version, the model was evaluated on peptide binding data corresponding to an individual allele only. On average, the performance of the trans-allele model is comparable to that of the intra-allele model for HLA-DP (0.930 vs 0.928), it is worse for HLA-DQ (0.830 vs 0.857) and it is better for HLA-DR (0.780 vs 0.771) (Figure 2).

These results demonstrate two important observations. First, there is a common binding preference among MHC-II loci, which is the basis of all trans-allelic models, and that has been successfully captured by the definition of MHC-II polymorphic groups for HLA-DP loci, and to a lesser extent for HLA-DQ and




Figure 1: (**colours online**) Shows Five-fold cross validation results of the model using the benchmark dataset described in the Section 4. Three ROC curves representing the three MHC-II loci covered in this study. The red curve for HLA-DP with AUC value = 0.930, the blue curve for HLA-DQ with AUC value = 0.830 and the green curve for HLA-DR with AUC = 0.802.

HLA-DR. Second, the trans-allelic model is able to extrapolate similarities among the MHC-II allotypes and achieve good predictive performance. As a result, the overall performance of the trans-allelic model is comparable to that of intra-allelic model, even though the former model is applied on a much diverse set of MHC-II sequences.

A decreased performance of the trans-allelic model when compared with the intra-allelic method for HLA-DQ molecules is consistent with results reported in NetMHCIIpan [17]. Here we suggest that this is probably because of the limited structural information available for HLA-DQ alleles. In fact, because of this limited structural information there are only 17 polymorphic residue groups for all the 9 binding pockets defined for HLA-DQ alleles. In contrast, there are 25 and 115 polymorphic residue groups defined for HLA-DP and HLA-DR molecules, respectively.

Another reason for the reduction of the trans-allelic model's performance for HLA-DQ alleles is that there is a large sequence diversity of MHC-II molecules belonging to this locus. We will examine the empirical support for this assertion in Section 5.3.

5.3 Prediction on a novel dataset

We examined the predictive power of the model on a blind dataset- i.e, a dataset which was not used in the training phase. More precisely, to make peptide binding predictions for a particular allele, we train the model on an entirely different allele. The allele used for training was chosen based on its similarity to the focal allele as quantified using three different metrics: nearest neighbour, Hamming distance, and

intra-allele vs trans-allele method




Figure 2: (colours online) Comparing results between the intra-alleles (gray bars) and the trans-alleles (red bars) methods in terms of AUC values. These bars show that there is a significant increase in performance of the trans-allele method for HLA-DR molecules and decrease for HLA-DQ molecules compared to the intra-allele method. The difference in the HLA-DP loci is limited.

Leave-One-Out (LOO) approach.

In the nearest neighbour approach the distance between two MHC molecules is defined [16] as follows:

$$d(A, B) = 1 - \frac{S(A, B)}{\sqrt{S(A, A)S(B, B)}} \quad (7)$$

in which $S(A, B)$ is the score of the BLOSUM50 [40] metric between amino acid sequences of A and B . The BLOSUM50 metric measures genetic distance between two sequences by quantifying the likelihood that one amino acid will be substituted by another amino acid on evolutionary time scales. Hamming distance simply counts the different occurrences of corresponding amino acid residues between two sequences. In both nearest neighbour and Hamming metrics, we train the model on peptide data belonging to the corresponding nearest allele to parameterize the model, then we assess its accuracy in terms of AUC values calculated based on peptide data belonging to the focal allele using those parameters.

However, unlike the TEPITOPE and the series of NetMHCIIpan methods which defined nearest neighbour at pocket level, we derive both the nearest neighbour metric and the Hamming distance at residue

level. Our choice is based on the fact that accounting for the entire MHC-II sequence provides a broader allele coverage [2] and hence extend the model's applicability. Computing sequence similarity at residue level is an intuitive and natural approach to perform comparative analysis of sequences rather than other artificial ways that may be more computationally efficient. We found that 71% (for HLA-DR), 60% (HLA-DP), and 67% (HLA-DQ) of alleles used for training were consistent between the residue-level and pocket-level approaches. These statistics indicate that, as mentioned before, most of MHC-II polymorphism occur at the binding pockets.

The LOO approach involved partitioning data into two parts; the peptide binding data not belonging to the allele under consideration are used to learn the model's parameters and the remaining data, the peptide binding data belonging to the focal allele, are used as test data. Figure 3 shows a comparison of results from these three approaches (details are in Table ?? in the supplementary material). The results show that, regardless of the metric we used, the trans-allele method has a high predictive power for HLA-DP allele and a moderate predictive power for the other alleles.

Comparison results of the three metrics.




Figure 3: (colours online) Average performance results of the model in terms of AUC values for the three metrics: NN approach (gray bars), Hamming metric (blue bars) and the LOO method (red bars). Except for HLA-DQ loci, the LOO approach significantly out performs the other two metrics. Such results indicate that this method performs better than a random test even for un-characterized MHC-II molecules.

The much higher predictive power for HLA-DP compared to the other alleles is likely due to the comparatively lower sequence diversity of HLA-DP alleles. To make this assertion more precise we carried out a regression analysis by defining the AUC values from LOO approach as functions of both NN and Hamming metric distances. Figure 4 gives results of our analysis. As seen in Figure 4, all HLA-DQ alleles fall below the least squares lines for both metrics (blue points). We also found that model performance increases as the distance between alleles decreases, for example, see HLA-DP allele (red points). The authors of NetMHCIIpan also arrived at the same conclusion [17], but only for the NN metric.




Figure 4: (colours online) Regression analysis of AUC values from the LOO approach as function of: **(a)** Nearest Neighbour and **(b)** Hamming distances. Negative slope lines in both graphs obtained by the least square fit method, with p-values 0.185 and 0.0033 for both metrics, respectively. These lines and p-values associated with were produced using glm2 package in R [41]

5.4 Analysis of the model's parameters

In order to determine the key factors that contribute to the binding affinities for the three MHC-II alleles considered in this study, we calculated the Hamiltonians corresponding to each amino acid residue and the 9 binding pockets of the MHC-II binding groove. These values were then averaged over the polymorphic residue groups defined for each pocket.

Analysis of HLA-DR parameters revealed that pocket *P1* has moderate attractive interactions with peptide (negative energies indicated by blue colour in Figure 5), via hydrophobic (**I, L, W, Y**) side chains and, to lesser extent, via the aromatic (**F, W**) amino acids and a single hydrophilic residue (**K**). Remarkably, previous studies [2, 42] arrived at a similar conclusion of a large tendency of position *P1* toward interactions involving the hydrophobic side chains. The repulsive interactions (positive energies indicated by red colour in Figure 5) of pocket *P1* mostly occur with the hydrophilic side chains (**D, E, N, S, T**) and the aliphatic residue (**A**). Generally, most of the primary anchor pockets (*P1, P4, P6, P7, P9*) confer attractive interactions, but the pocket *P1* makes the largest contribution. This is consistent with results obtained using the MULTIRTA method [2]. Among the secondary anchors, we found that pocket *P2* has attractive interactions with aromatic (**F, Y**) and the hydrophobic (**I, M, Y**) side chains. The most repulsive interactions come from the pocket *P8*, which has a strong unfavourable interactions involving the side chains of residues **C, D, E, F, G, I, L, W, and Y** (see Figure 5 (a)).

For HLA-DP, we found that pocket *P9* has significantly attractive interactions involving the hydrophobic residue (**L**). This is consistent with the previous results of [43] (see Figure 5 (b)). Also, we found that pockets *P4* and *P5* have important attractive interactions with peptide via hydrophobic (**Y**) and aromatic (**F**) side chains, respectively. The contributions of these two pockets were not reported in the study of Morten et. al [43], which was specifically dedicated to HLA-DQ and HLA-DP alleles. Furthermore, we found that the other two pockets *P1* and *P6*, which were reported as primary anchors in that study, have a moderate contribution to calculated bind energies (see Figure 5 (b)).

The pattern of energetic contributions for HLA-DQ alleles is less ordered. There is no common pattern except the observation of significant attractive interaction of pocket *P1* via the hydrophobic residue (**W**) and the repulsive interaction of pocket *P4* via the side chains **C, E, and D** (see Figure 5 (c)). This finding is in line with the observations of Morten et. al [43].




Figure 5: (colours online) Interaction maps for: **(a)** HLA-DR, **(b)** HLA-DP and **(c)** HLA-DQ molecules. The rows give the 9 anchor positions of MHC-II binding groove and the columns give the peptide residues. The red entries marking for repulsive interactions (positive energy), whereas the blue entries marking for attractive interactions (negative energy). Note that most of the entries are zeros (white colour), an indication for the degree of the sparsity of the model.

5.5 Discussion

Interactions between peptides and MHC-II molecules are central to the adaptive immune system. Precise prediction and knowledge of the physico-chemical determinants that govern such interaction is useful in designing effective and affordable epitope-based vaccines, and in providing insights about the immune system’s mechanism as well as in understanding the pathogenesis of diseases. In this study we have developed a trans-allelic model that can predict peptide interactions to the three human MHC-II loci. It can be readily applied to MHC-II molecules of other species provided that relative structural information are available. This method is based on biophysical ideas, an alternative to the dominant machine learning approaches.

The model presented here is, in addition to NetMHCIIpan, only the second trans-allelic method that allows comprehensive prediction analysis of peptide binding to all three human MHC-II loci. Most trans-allelic models for MHC-II peptides are restricted to HLA-DR and HLA-DP alleles. The TEPITOPEpan method [23], which is popular among immunologists and is the successor of a pioneer method in this field, is limited to HLA-DR alleles.

In this work we employed the definition of MHC polymorphic residue groups of the MULTIRTA method [2], which is more intuitive and inclusive than the MHC pseudo sequences of NetMHCIIpan [17], in developing our trans-allelic model. Utilizing new structural data for MHC-II complexes, which were not present when MULTIRTA was being developed, we extended that idea to cover all three human MHC-II loci.

We Compared how well our model predicts the MHC-II allele binding preferences of a novel peptide dataset vs. how well the state-of-the-art NetMHCIIpan method performs the same task. In this comparison we applied both our model and NetMHCIIpan to predict binding preferences for peptides known to either bind or not bind a reference allele after training both models using peptide-binding data for a second allele. For a given MHC-II locus, the second allele was the one that was most similar to the reference allele. Similarity was quantified based on either a leave-one-out approach or a nearest-neighbour approach (see Section 5.3). When using the nearest-neighbour approach, we found that our model performs significantly better than NetMHCIIpan in predicting peptide binding preferences for HLA-DQ alleles (P-value = 0.015; Figure 6, panel A). Furthermore, at the 95% confidence level, for all other cases, we found no significant difference between the performances of the two models (Figure 6).

These results are reassuring and indicate that our inverse-physics approach constitutes a promising complement to the widely used pattern-based approach to peptide-MHC-II binding predictions. The outstanding predictive accuracy of the NetMHCIIpan is not the result of its theoretical basis. Rather it derives from the use of sophisticated ensembles of neural networks, which are very powerful. However, our method has a distinguishing advantage over all the advanced machine learning models in that it is more physically meaningful. It is worth noting that our prediction results of peptide-MHC-II interaction were based on *in-silico* analysis of real data. Additional, *in-vivo* and *in-vitro* investigations are needed to further validate the reported predictive performance.

Current model vs NetMHCIIpan




Figure 6: Performance comparison between our model and NetMHCIIpan. Each model was used to predict the probability of peptide binding to query alleles belonging to each of three HLA loci (i.e. HLA-DP, HLA-DQ, HLA-DR) after training it using peptide-binding data for a different allele. The allele that was most similar to the query allele was used for training. As in previous work [17], similarity between HLA alleles was defined based on two metrics: nearest neighbor (NN) and leave-one-out (LOO). See the text for definitions of these metrics. For each query allele, we measured each model's predictive performance (accounting for both sensitivity and specificity) by calculating an AUC value. The higher the AUC value the better the predictive performance. The plot shows the average difference between the AUC values for alleles belonging to the same locus obtained using our model vs. the corresponding values obtained using NetMHCIIpan, when similarity is defined based on either (A) the NN or (B) the LOO metric. Error bars denote standard deviations. Strikingly, our model performs better than NetMHCIIpan when predicting peptide binding to HLA-DQ using the NN metric (p-value = 0.015). For all other cases, both models have equivalent performance.

References

- [1] C Janeway, P Travers, M Walport, and M Shlomchik. *Immunobiology: the immune system in health and disease*. Garland Science Publishing, 2005.
- [2] Andrew J Bordner and Hans D Mittelmann. MultiRTA: A simple yet reliable method for predicting peptide binding affinities for multiple class II MHC allotypes. *BMC Bioinformatics*, 11(482), September 2010. doi: 10.1186/1471-2105-11-482.
- [3] O Lund, M Nielsen, C Lundegaard, C Kesmir, and S Brunak. *Immunological bioinformatics*. MIT Press, 2005.

- [4] Thomas J Kindt, Richard A Goldsby, Barbara Anne Osborne, and Janis Kuby. *Kuby Immunology*. W H Freeman, 2007.
- [5] Atanas Patronov and Irini Doytchinova. T-cell epitope vaccine design by immunoinformatics. *Open Biology*, 31(10), January 2013. doi: 10.1098/rsob.120139.
- [6] John A Todd, John I Bell, and Hugh O Mcdevitt. HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. *Nature Biotechnology*, 329(6140):599–604, October 1987. doi: 10.1038/329599a0.
- [7] A Fogdell, J Hillert, C Sachs, and O Olerup. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. *Tissue Antigens*, 46(482):333–336, 1995. doi: 10.1111/j.1399-0039.1995.tb02503.x.
- [8] S C L Gough and M J Simmonds. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. *Curr Genomics*, 8(7):453–465, November 2007. doi: 10.2174/138920207783591690.
- [9] Jones E Yvonne, Fugger Lars, Strominger Jack L, and Siebold Christian. MHC class II proteins and disease: a structural perspective. *Nat Rev Immunol*, 6(4):271–282, apr 2006. doi: 10.1038/nri1805.
- [10] Maja Mandic, Florence Castelli, Bratislav Janjic, Christine Almunia, Pedro Andrade, Daniel Gillet, Vladimir Brusic, John M Kirkwood, Bernard Maillere, and Hassane M Zarour. One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma. *The Journal of Immunology*, 174(3):1751–1759, 2005. doi: 10.4049/jimmunol.174.3.1751.
- [11] Ruth E Soria-Guerra, Ricardo Nieto-Gomez, Dania O Govea-Alonso, and Sergio Rosales-Mendoza. An overview of bioinformatics tools for epitope prediction: Implications on vaccine development. *Journal of Biomedical Informatics*, 53:405–414, 2015. doi: 10.1016/j.jbi.2014.11.003.
- [12] Ivan Dimitrov, Panayot Garnev, Darren R Flower, and Irini Doytchinova. MHC Class II Binding Prediction—A Little Help from a Friend. *Journal of Biomedicine and Biotechnology*, 2010, January 2010. doi: 10.1155/2010/705821.
- [13] Falk Kirsten, Rotzschke Olaf, Stevanovic Stefan, Jung Gunther, and Rammensee Hans-Georg. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature*, 351(6324):290–296, may 1991. doi: 10.1038/351290a0.
- [14] Ji Wan, Wen Lin, Qiqi Xu, Yongliang Ren, Darren R Flower, and Tongbin Li. SVRMHC prediction server for MHC-binding peptides. *BMC Bioinformatics*, 7(463), October 2006. doi: 10.1186/1471-2105-7-463.
- [15] Hideki Noguchi, Ryuji Kato, Taizo Hanai, Yukari Matsubara, Hiroyuki Honda, Vladimir Brusic, and Takeshi Kobayashi. Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. *Journal of Bioscience and Bioengineering*, 94(3):264–270, September 2002. doi: 10.1016/S1389-1723(02)80160-8.
- [16] Morten Nielsen, Claus Lundegaard, Thomas Blicher, Bjoern Peters, Alessandro Sette, Sune Justesen, Søren Buus, and Ole Lund. Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan. *PLoS Comput Biol*, 47, July 2008. doi: 10.1371/journal.pcbi.1000107.
- [17] Edita Karosiene, Michael Rasmussen, Thomas Blicher, Ole lund, Søren Buus, and Morten Nielsen. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. *Immunogenetics*, 65(10), July 2013. doi: 10.1007/s00251-013-0720-y.
- [18] I Doytchinova and Flower Darren. The HLA-A2-supermotif: a QSAR definition. *Org. Biomol. Chem*, 7:2648–2654, 2003. doi: 10.1039/b300707c.

- [19] Andrew J Bordner and Hans D Mittelman. Prediction of the binding affinities of peptides to class II MHC using a regularized thermodynamic model. *BMC Bioinformatics*, 11(41), January 2010. doi: 10.1186/1471-2105-11-41.
- [20] Abdoelnaser M Degoot, Faraimunashe Chirove, and Wilfred Ndifon. A Biophysical Model for Predictions of Peptide: HLA-DR Interactions Based on Genomic and Structural Data. *BMC Bioinformatics*, September 2017.
- [21] Noah Zaitlen, Manuel Reyes-Gomez, David Heckerman, and Nebojsa Jojic. Shift-Invariant Adaptive Double Threading: Learning MHC II–Peptide Binding. *Journal of Computational Biology*, 15(7):927–942, September 2008. doi: 10.1089/cmb.2007.0183.
- [22] Lianming Zhang, Keiko Udaka, Hiroshi Mamitsuka, and Shanfeng Zhu. Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools. *Briefings in Bioinformatics*, 13(3):350–364, May 2012. doi: 10.1093/bib/bbr060.
- [23] Lianming Zhang, Yiqing Chen, Hau-San Wong, Shuigeng Zhou, Hiroshi Mamitsuka, and Shanfeng Zhu. TEPITOPEpan: Extending TEPITOPE for Peptide Binding Prediction Covering over 700 HLA-DR Molecules. *PLoS One*, 7(2), February 2012. doi: 10.1371/journal.pone.0030483.
- [24] Tiziana Sturniolo, Elisa Bono, Jiayi Ding, Laura Radrizzani, Oezlem Tuereci, Ugur Sahin, Michael Braxenthaler, Fabio Gallazzi, Maria Pia Protti, Francesco Sinigaglia, and Juergen Hammer. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. *Nature Biotechnology*, 17(6):555–561, June 1999. doi: 10.1038/9858.
- [25] Morten Nielsen, Sune Justesen, Ole Lund, Claus Lundegaard, and Søren Buus. NetMHCIIpan-2.0 - improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. *Immunome Research*, 6(9), November 2010. doi: 10.1186/1745-7580-6-9.
- [26] Massimo Andreatta, Edita Karosiene, Michael Rasmussen, Anette Stryhn, Søren Buus, and Morten Nielsen. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. *Immunogenetics*, 67(0):641–650, November 2015. doi: 10.1007/s00251-015-0873-y.
- [27] Morten Nielsen, Claus Lundegaard, and Ole Lund. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. *BMC Bioinformatics*, 8(238), July 2007. doi: 10.1186/1471-2105-8-238.
- [28] Mohammed AlQuraishi, Grigoriy Koytiger, Anne Jenney, Gavin MacBeath, and Peter K Sorger. A multiscale statistical mechanical framework integrates biophysical and genomic data to assemble cancer networks. *Nature Genetic*, 46:1363–1371, 2014. doi: 10.1038/ng.3138.
- [29] H Chau Nguyen, Riccardo Zecchina, and Johannes Berg. Inverse statistical problems: from the inverse Ising problem to data science. *Advances in Physics*, 66(3):197–261, July 2017. doi: 10.1080/00018732.2017.1341604.
- [30] A Sette, L Adorini, S M Colon, S Buus, and H M Grey. Capacity of intact proteins to bind to MHC class II molecules. *The Journal of Immunology*, 143(4):1265–1267, 1989.
- [31] Peter W Rose, Andreas Prlić, Chunxiao Bi, Wolfgang F Bluhm, Cole H Christie, Shuchismita Dutta, Rachel Kramer Green, David S Goodsell, John D Westbrook, Jesse Woo, Jasmine Young, Christine Zardecki, Helen M Berman, Philip E Bourne, and Stephen K Burley. The RCSB Protein Data Bank: views of structural biology for basic and applied research and education. *Nucleic Acids Res*, 43 (Database issue):D345–D356, January 2015. doi: 10.1093/nar/gku1214.
- [32] Yilei Zhao Gaofeng Pan Jijun Tang Zhao Li and Fei Guo. A Novel Peptide Binding Prediction Approach for HLA-DR Molecule Based on Sequence and Structural Information. *BioMed Research International*, 2016(3832176), May 2016. doi: 10.1155/2016/3832176.

- [33] U Bodenhofer, E Bonatesta, C Horejs-Kainrath, and S Hochreiter. msa: an R package for multiple sequence alignment. *Bioinformatics*, 31(24):3997–3999, 2015. doi: 10.1093/bioinformatics/btv494.
- [34] Robert Tibshirani. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society. Series B (Methodological)*, pages 267–288, 1996.
- [35] Jerome Friedman, Trevor Hastie, and Rob Tibshirani. Regularization Paths for Generalized Linear Models via Coordinate Descent. *Journal of Statistical Software*, 33(10):1–22, January 2010.
- [36] Randi Vita, James A Overton, Jason A Greenbaum, Julia Ponomarenko, Jason D Clark, Jason R Cantrell, Daniel K Wheeler, Joseph L Gabbard, Deborah Hix, Alessandro Sette, and Bjoern Peters. The immune epitope database (IEDB) 3.0. *Nucleic Acids Res*, 43(Database issue):D405–D12, January 2015. doi: 10.1093/nar/gku938.
- [37] Morten Nielsen, Claus Lundegaard, Peder Worning, Sanne Lise Lauemøller, Kasper Lamberth, Søren Buus, Søren Brunak, and Ole Lund. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. *Protein Science*, 12(3):1007–1017, May 2003. doi: 10.1110/ps.0239403.
- [38] James Robinson, Jason A. Halliwell, Hamish McWilliam, Rodrigo Lopez, and Steven G. E. Marsh. IPD—the Immuno Polymorphism Database. *Nucleic Acids Research*, 41(D1):D1234–D1240, 2013. doi: 10.1093/nar/gks1140.
- [39] Tom Fawcett. An introduction to ROC analysis. *Pattern Recognition Letters*, 2006. doi: 10.1016/j.patrec.2005.10.010.
- [40] Henikoff Steven and Henikoff Jorja. Amino acid substitution matrices from protein blocks. *Proceedings of the National Academy of Sciences of the United States of America*, 89(22):10915–10919, nov 1992.
- [41] Ian C Marschner. glm2: Fitting generalized linear models with convergence problems. *CRAN*, May 2014.
- [42] Dean R Madden. The three-dimensional structure of peptide-MHC complexes. *Annual Review of Immunology*, 13:587–622, 1995. doi: 10.1146/annurev.iy.13.040195.003103.
- [43] Massimo Andreatta and Morten Nielsen. Characterizing the binding motifs of 11 common human HLA-DP and HLA-DQ molecules using NNAlign. *Immunology*, 136(3):306–311, July 12. doi: 10.1111/j.1365-2567.2012.03579.x.
- [44] Myles Hollander and Douglas A Wolfe. *Nonparametric Statistical Methods*. John Wiley & Sons, 1999.